PaxMedica Prepares NDA Submission for Suramin to Treat Human African Trypanosomiasis
PaxMedica prepares to submit NDA for suramin to treat Human African Trypanosomiasis, a significant step forward in addressing the disease. Learn more about the company's progress and its upcoming Type C meeting with the FDA.
This news matters as it represents progress towards finding a treatment for a debilitating disease that affects many people in East Africa. If successful, this treatment could greatly impact the lives of those affected by Human African Trypanosomiasis.
